Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

NCT00869726 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00869726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00869726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis
Lead sponsor
Eli Lilly and Company
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2004
Completion date
May 31, 2009
Enrollment
596 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

secondary progressive multiple sclerosis